1. A comparison of tissue engineering based repair of calvarial defects using adipose stem cells from normal and osteoporotic rats.

    Bone 78:1 (2015) PMID 25940459 PMCID PMC4466199

    Repairing large bone defects presents a significant challenge, especially in those people who have a limited regenerative capacity such as in osteoporotic (OP) patients. The aim of this study was to compare adipose stem cells (ASCs) from both normal (NORM) and ovariectomized (OVX) rats in osteog...
  2. Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.

    Antimicrobial Agents and Chemotherapy 59(8):4424 (2015) PMID 25987632 PMCID PMC4505228

    Posaconazole (PCZ), approved for prophylaxis against invasive fungal disease in high-risk patients, is commercially available orally as a suspension formulation (PCZ-susp) and as a delayed-release tablet (PCZ-tab). We evaluated the serum steady-state concentrations (Css) of PCZ stratified by the...
  3. Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study.

    Cancer 121(14):2411 (2015) PMID 25832466 PMCID PMC4490036

    Receptors in tumor blood vessels are attractive targets for ligand-directed drug discovery and development. The authors have worked systematically to map human endothelial receptors ("vascular zip codes") within tumors through direct peptide library selection in cancer patients. Previously, they...
  4. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3.

    PNAS 112(27):8403 (2015) PMID 26080435 PMCID PMC4500257

    Prostate cancer antigen 3 (PCA3) is the most specific prostate cancer biomarker but its function remains unknown. Here we identify PRUNE2, a target protein-coding gene variant, which harbors the PCA3 locus, thereby classifying PCA3 as an antisense intronic long noncoding (lnc)RNA. We show that P...
  5. A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan.

    Supportive Care Cancer 23(3):661 (2015) PMID 25160493

    Calcium aluminosilicate clay (CASAD) is a naturally occurring clay that serves as a cation exchange absorbent. We hypothesized that oral administration of CASAD would reduce the rate of grade 3/4 diarrhea associated with irinotecan use for metastatic colorectal cancer (CRC) by adsorbing the SN-3...
  6. A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan.

    Supportive Care Cancer 23(3):661 (2015) PMID 25160493

    Calcium aluminosilicate clay (CASAD) is a naturally occurring clay that serves as a cation exchange absorbent. We hypothesized that oral administration of CASAD would reduce the rate of grade 3/4 diarrhea associated with irinotecan use for metastatic colorectal cancer (CRC) by adsorbing the SN-3...
  7. Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer.

    European Urology 67(1):53 (2015) PMID 24882673 PMCID PMC4247811

    Enzalutamide is a novel antiandrogen with proven efficacy in metastatic castration-resistant prostate cancer (mCRPC). To evaluate enzalutamide's effects on cancer and on androgens in blood and bone marrow, and associate these with clinical observations. In this prospective phase 2 study, 60 pati...
  8. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.

    European Urology 67(1):53 (2015) PMID 24882673 PMCID PMC4247811

    Enzalutamide is a novel antiandrogen with proven efficacy in metastatic castration-resistant prostate cancer (mCRPC). To evaluate enzalutamide's effects on cancer and on androgens in blood and bone marrow, and associate these with clinical observations. In this prospective phase 2 study, 60 pati...
  9. Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer

    European Urology 67(1):53 (2015)

    Background Enzalutamide is a novel antiandrogen with proven efficacy in metastatic castration-resistant prostate cancer (mCRPC).
  10. Radiation exposure from diagnostic procedures in patients with newly diagnosed breast cancer.

    The Journal of community and supportive oncology 13(1):27 (2015) PMID 25839063

    Radiation exposure is associated with an increased risk of secondary cancers. Knowing the approximate radiation exposure from diagnostic procedures in the œrst year after a breast cancer diagnosis could help educate patients and allow physicians to monitor them more closely for potential risks. ...
  11. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.

    European Urology 67(1):53 (2015) PMID 24882673 PMCID PMC4247811

    Enzalutamide is a novel antiandrogen with proven efficacy in metastatic castration-resistant prostate cancer (mCRPC). To evaluate enzalutamide's effects on cancer and on androgens in blood and bone marrow, and associate these with clinical observations. In this prospective phase 2 study, 60 pati...
  12. Appalachian mountaintop mining particulate matter induces neoplastic transformation of human bronchial epithelial cells and promotes tumor formation.

    Environmental Science & Technology 48(21):12912 (2014) PMID 25347054 PMCID PMC4224494

    Epidemiological studies suggest that living near mountaintop coal mining (MTM) activities is one of the contributing factors for high lung cancer incidence. The purpose of this study was to investigate the long-term carcinogenic potential of MTM particulate matter (PMMTM) exposure on human bronc...
  13. Appalachian mountaintop mining particulate matter induces neoplastic transformation of human bronchial epithelial cells and promotes tumor formation.

    Environmental Science & Technology 48(21):12912 (2014) PMID 25347054 PMCID PMC4224494

    Epidemiological studies suggest that living near mountaintop coal mining (MTM) activities is one of the contributing factors for high lung cancer incidence. The purpose of this study was to investigate the long-term carcinogenic potential of MTM particulate matter (PMMTM) exposure on human bronc...
  14. Diabetes, diabetes treatment and breast cancer prognosis.

    Breast Cancer Research and Treatment 148(1):153 (2014) PMID 25261292 PMCID PMC4393950

    The objectives of this study are to assess the impact of pre-existing diabetes and diabetes treatment on breast cancer prognosis. 8,108 women with centrally confirmed invasive breast cancer in the Women's Health Initiative diagnosed between 1998 and 2013 were followed through the date of death o...
  15. Diabetes, diabetes treatment and breast cancer prognosis.

    Breast Cancer Research and Treatment 148(1):153 (2014) PMID 25261292

    The objectives of this study are to assess the impact of pre-existing diabetes and diabetes treatment on breast cancer prognosis. 8,108 women with centrally confirmed invasive breast cancer in the Women's Health Initiative diagnosed between 1998 and 2013 were followed through the date of death o...
  16. Weight change associated with third-generation adjuvant chemotherapy in breast cancer patients.

    The Journal of community and supportive oncology 12(10):355 (2014) PMID 25853257

    Studies have shown that breast cancer treatment can cause an increase in weight. Weight gain during chemotherapy is usually significant and may be associated with poor survival. However, the role of third- generation chemotherapy regimens and weight gain is not well reviewed. We retrospectively ...
  17. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses.

    Clinical Cancer Research 20(18):4827 (2014) PMID 24987059 PMCID PMC4518867

    The purpose of this study was to confirm our previous results that targeted agents matched with tumor molecular alterations were associated with improved outcomes compared with nonmatched therapy in patients with advanced cancer. Outcomes of patients who were referred for treatment on phase I cl...
  18. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses.

    Clinical Cancer Research 20(18):4827 (2014) PMID 24987059

    The purpose of this study was to confirm our previous results that targeted agents matched with tumor molecular alterations were associated with improved outcomes compared with nonmatched therapy in patients with advanced cancer. Outcomes of patients who were referred for treatment on phase I cl...
  19. Predictors and Impact of Thirty-Day Readmission on Patient Outcomes and Health Care Costs after Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation

    Biology of Blood and Marrow Transplantation 20(3):415 (2014)

    Thirty-day readmission (30-DR) has become an important quality-of-care measure. Allogeneic hematopoietic cell transplantation (allo-HCT) presents a medical setting with higher readmission rates. We analyzed factors affecting 30-DR and its impact on patient outcomes and on health care c...
  20. Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation.

    Biology of Blood and Marrow Transplantation 20(3):415 (2014) PMID 24361913

    Thirty-day readmission (30-DR) has become an important quality-of-care measure. Allogeneic hematopoietic cell transplantation (allo-HCT) presents a medical setting with higher readmission rates. We analyzed factors affecting 30-DR and its impact on patient outcomes and on health care costs in 91...